MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

Kodu・Aktsiate loetelu・Essa Pharma Inc

Essa Pharma Inc

Suletud

1.66 -2.35

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.66

Max

1.73

Põhinäitajad
By Trading Economics
Sissetulek	2.2M -6.4M
Aktsiakasum	-0.195
Töötajad	35
EBITDA	-2.2M -8.5M

Turustatistika
By TradingEconomics
Turukapital	-444K 75M
Eelmine avamishind	4.01
Eelmine sulgemishind	1.66

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

1.7 / 1.72 Toetus ja vastupanu

Essa Pharma Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. juuli 2025, 23:09 UTC

Tulu

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1. juuli 2025, 19:16 UTC

Omandamised, ülevõtmised, äriostud

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1. juuli 2025, 23:47 UTC

Market Talk

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1. juuli 2025, 23:41 UTC

Market Talk

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1. juuli 2025, 22:23 UTC

Omandamised, ülevõtmised, äriostud

James Hardie: Deal Represents Implied Value of $8.4 Billion

1. juuli 2025, 22:23 UTC

Omandamised, ülevõtmised, äriostud

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1. juuli 2025, 22:21 UTC

Omandamised, ülevõtmised, äriostud

James Hardie Completes Acquisition of AZEK

1. juuli 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1. juuli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. juuli 2025, 20:24 UTC

Tulu

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1. juuli 2025, 19:55 UTC

Market Talk

Oil Futures Resume Cautious Rally -- Market Talk

1. juuli 2025, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1. juuli 2025, 19:12 UTC

Market Talk

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1. juuli 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1. juuli 2025, 18:41 UTC

Omandamised, ülevõtmised, äriostud

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1. juuli 2025, 18:33 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

1. juuli 2025, 18:33 UTC

Market Talk

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1. juuli 2025, 18:32 UTC

Market Talk

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1. juuli 2025, 18:22 UTC

Market Talk

Remittances to Mexico Down in May -- Market Talk

1. juuli 2025, 17:45 UTC

Market Talk

Seasonal Demand Supports Further Oil Gains -- Market Talk

1. juuli 2025, 17:01 UTC

Omandamised, ülevõtmised, äriostud

Danone Completed Acquisition of Majority Stake in Kate Farms

1. juuli 2025, 16:55 UTC

Tulu

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1. juuli 2025, 16:27 UTC

Market Talk

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1. juuli 2025, 16:25 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1. juuli 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

1. juuli 2025, 15:48 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1. juuli 2025, 15:46 UTC

Market Talk

Global Equities Roundup: Market Talk

1. juuli 2025, 15:46 UTC

Market Talk

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1. juuli 2025, 14:54 UTC

Market Talk

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1. juuli 2025, 14:49 UTC

Market Talk

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Essa Pharma Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Essa Pharma Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.7 / 1.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Essa Pharma Inc

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.